These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38873256)

  • 1. Impact of the COVID-19 pandemic on cervical cancer screening participation, abnormal cytology prevalence and screening interval in Catalonia.
    Robles C; Monfil L; Ibáñez R; Roura E; Font R; Peremiquel-Trillas P; Brotons M; Martínez-Bueno C; de Sanjosé S; Espinàs JA; Bruni L
    Front Oncol; 2024; 14():1338859. PubMed ID: 38873256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT.
    Gilham C; Sargent A; Kitchener HC; Peto J
    Health Technol Assess; 2019 Jun; 23(28):1-44. PubMed ID: 31219027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decision-analytic modeling to evaluate the long-term effectiveness and cost-effectiveness of HPV-DNA testing in primary cervical cancer screening in Germany.
    Sroczynski G; Schnell-Inderst P; Mühlberger N; Lang K; Aidelsburger P; Wasem J; Mittendorf T; Engel J; Hillemanns P; Petry KU; Krämer A; Siebert U
    GMS Health Technol Assess; 2010 Apr; 6():Doc05. PubMed ID: 21289878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coverage of Cervical Cancer Screening in Catalonia for the Period 2008-2011 among Immigrants and Spanish-Born Women.
    Rodríguez-Salés V; Roura E; Ibañez R; Peris M; Bosch FX; de Sanjosé S
    Front Oncol; 2013; 3():297. PubMed ID: 24392348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors].
    Ronco G; Biggeri A; Confortini M; Naldoni C; Segnan N; Sideri M; Zappa M; Zorzi M; Calvia M; Accetta G; Giordano L; Cogo C; Carozzi F; Gillio Tos A; Arbyn M; Mejier CJ; Snijders PJ; Cuzick J; Giorgi Rossi P
    Epidemiol Prev; 2012; 36(3-4 Suppl 1):e1-72. PubMed ID: 22828243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice.
    Katki HA; Kinney WK; Fetterman B; Lorey T; Poitras NE; Cheung L; Demuth F; Schiffman M; Wacholder S; Castle PE
    Lancet Oncol; 2011 Jul; 12(7):663-72. PubMed ID: 21684207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of positive screening test results and agreement between cytology and human papillomavirus testing in primary cervical cancer screening in North-Western Romania.
    Şuteu O; Blaga ML; Nygård M; Leinonen MK; Nicula F; Păiş R; Coza D; Cadariu PA; Melnic A; Andreassen T; Hashim D; Weiderpass E
    Eur J Cancer Prev; 2020 Mar; 29(2):141-148. PubMed ID: 31033568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pilot study of HPV DNA and cytology testing in 50,159 women in the routine Mexican Social Security Program.
    Lazcano-Ponce E; Lörincz AT; Salmerón J; Fernández I; Cruz A; Hernández P; Mejia I; Hernández-Avila M
    Cancer Causes Control; 2010 Oct; 21(10):1693-700. PubMed ID: 20617376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Age at last screening and remaining lifetime risk of cervical cancer in older, unvaccinated, HPV-negative women: a modelling study.
    Malagón T; Kulasingam S; Mayrand MH; Ogilvie G; Smith L; Bouchard C; Gotlieb W; Franco EL
    Lancet Oncol; 2018 Dec; 19(12):1569-1578. PubMed ID: 30392810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial.
    Lazcano-Ponce E; Lorincz AT; Cruz-Valdez A; Salmerón J; Uribe P; Velasco-Mondragón E; Nevarez PH; Acosta RD; Hernández-Avila M
    Lancet; 2011 Nov; 378(9806):1868-73. PubMed ID: 22051739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Age-specific effectiveness of primary human papillomavirus screening versus cytology in a cervical cancer screening program: a nationwide cross-sectional study.
    Bao H; Ma L; Zhao Y; Song B; Di J; Wang L; Gao Y; Ren W; Wang S; Wu J; Wang HJ
    Cancer Commun (Lond); 2022 Mar; 42(3):191-204. PubMed ID: 35142100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence and Associated Factors of Abnormal Cervical Cytology and HighRisk HPV DNA among Bangkok Metropolitan Women.
    Tangjitgamol S; Kantathavorn N; Kittisiam T; Chaowawanit W; Phoolcharoen N; Manusirivithaya S; Khunnarong J; Srijaipracharoen S; Saeloo S; Krongthong W; Supawattanabodee B; Thavaramara T; Pataradool K
    Asian Pac J Cancer Prev; 2016; 17(7):3147-53. PubMed ID: 27509943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use Trends and Recent Expenditures for Cervical Cancer Screening-Associated Services in Medicare Fee-for-Service Beneficiaries Older Than 65 Years.
    Qin J; Holt HK; Richards TB; Saraiya M; Sawaya GF
    JAMA Intern Med; 2023 Jan; 183(1):11-20. PubMed ID: 36409511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of high-risk human papillomavirus (HR-HPV) infection among women with normal and abnormal cervical cytology in Myanmar.
    Mu-Mu-Shwe ; Harano T; Okada S; Aye-Aye-Win ; Khin-Saw-Aye ; Hlaing-Myat-Thu ; Mo-Mo-Win ; Khin-Khin-Oo ; Myo-Khin
    Acta Med Okayama; 2014; 68(2):79-87. PubMed ID: 24743783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How will transitioning from cytology to HPV testing change the balance between the benefits and harms of cervical cancer screening? Estimates of the impact on cervical cancer, treatment rates and adverse obstetric outcomes in Australia, a high vaccination coverage country.
    Velentzis LS; Caruana M; Simms KT; Lew JB; Shi JF; Saville M; Smith MA; Lord SJ; Tan J; Bateson D; Quinn M; Canfell K
    Int J Cancer; 2017 Dec; 141(12):2410-2422. PubMed ID: 28801947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of the Corona Pandemic on Cervical Cancer Screening Assessment.
    Stuebs FA; Behrens AS; Seibold A; Adler W; Geppert C; Hartmann A; Knöll A; Koch MC; Mehlhorn G; Beckmann MW; Theuser AK; Schulmeyer CE; Gass P; Dietl AK
    In Vivo; 2024; 38(2):734-740. PubMed ID: 38418110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population-based primary HPV mRNA cervical screening compared with cytology screening.
    Lindroth Y; Borgfeldt C; Thorn G; Bodelsson G; Forslund O
    Prev Med; 2019 Jul; 124():61-66. PubMed ID: 31047910
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.